Posts

Posted on

ClearOne Enhances “The New Normal” Hybrid Work and Learning Environment with New Entry-Level and High-End Cameras

Cameras deliver new video options and specialized features to make remote collaboration better than ever particularly when paired with a free COLLABORATE Space lifetime cloud-based video application subscription.

SALT LAKE CITY, Jan. 12, 2021 (GLOBE NEWSWIRE) — Ushering in the new year with a commitment to make true-to-life video collaboration possible for everyone, ClearOne (NASDAQ: CLRO), a global provider of audio and visual communications solutions, today announced the immediate availability of two new powerful cameras that enhance the ease and visual quality of online collaboration beyond the capabilities of integrated laptop and PC cameras.

With the new ClearOneUNITE® 10, the company’s most affordable camera ever, and the feature-rich ClearOneUNITE 50 4K AF that includes Auto-Framing technology for automatic single- or multi-person capture, everyone can take on the new year with the confidence provided by stunning video that puts them in the best possible light.

“A new year presents all of us with the opportunity to improve the way we come across to our teammates in an online work or learning environment,” ClearOne Chair and CEO Zee Hakimoglu said. “During the pandemic, we recognized that millions of people were expected to use video collaboration tools, for the first time, and the rapid societal shift to home-based and remote work left a lot of people desiring higher quality video solutions to ensure they make a good impression and enjoy reliable, clear and efficient communication.”

For users who want to upgrade from the basic camera included in their laptop or PC, ClearOne has lowered the barrier of entry with its most affordable webcam ever, the UNITE 10. The small, powerful webcam supports up to 1080p video quality and offers autofocus.

The UNITE 10 can capture five-megapixel images with a field of view up to 87 degrees, while major competitors at this price point only achieve 78-degree field of view. The UNITE 10 attaches any PC or laptop with a simple mounting bracket, and a 1.5m USB-A cable ensures simple connection to most modern computers. The UNITE 10 is also available to dealers and distributors in 20 packs for commercial sale.

The new UNITE 50 4K AF camera is a major upgrade over traditional webcams and introduces ClearOne’s new Auto-Framing technology that automatically frames meeting participants to maximize screen use through intelligent image algorithms and ePTZ automation (electronic pan, tilt and zoom).  With 4K video quality at 30 Hz, auto-focus capability, 4x digital zoom, more than 8 megapixels of total resolution and an ultra-wide 110-degree field of view, the UNITE 50 4K AF ePTZ is equally capable of delivering incredible image quality from a home office as it is at capturing all participants in an office boardroom.

The UNITE 50 4K AF is an ideal choice for managers or executives who require the absolute best remote video presentation available and also want a solution that can be used for in-office meetings. The camera can be controlled through an IR remote, further simplifying use and enabling real-time control of pan, tilt and zoom to provide greater control when capturing multi-person meeting environments. A standard damping mount ensures fast, easy installation, while an included USB 3.0 cable provides both power and video.

Both new ClearOne cameras enable life-like video quality to web-based conferencing applications including ClearOne’s COLLABORATE® Space, WebEx™, Google Meet, Zoom™, GoToMeeting™, and Microsoft® Teams.

ClearOne’s COLLABORATE Space is a powerful, award-winning collaboration tool that delivers a full suite of audio, video conferencing, web conferencing, and meeting tools in a persistent space.  COLLABORATE Space comes with everything needed for online meetings, including messaging, integrated file sharing, whiteboarding, annotation, meeting minutes, scheduling, and more.

To download a free COLLABORATE Space lifetime subscription with unlimited video meeting time, click here.

“Whether a student wants their instructor and classmates to see them more clearly or an office manager needs a multi-purpose camera with the benefit of artificial intelligence framing functions, ClearOne’s newest products of 2021 are accommodating ‘the new normal’ with HD quality and accessibility for any budget,” Hakimoglu added.

To learn more about UNITE 10, click here. To learn more about UNITE 50 4K AF, click here.

About ClearOne

ClearOne is a global market leader enabling conferencing, collaboration, and network streaming solutions. The performance and simplicity of its advanced, comprehensive solutions offer unprecedented levels of functionality, reliability, and scalability. Visit ClearOne at www.clearone.com.

###

 

 

Attachments 



Contact:
Bob Griffin
Griffin360
Twitter: @griffin360
212.481.3456 x16
[email protected]

Posted on

Quotient Limited Wins 2021 BIG Innovation Award

JERSEY, Channel Islands, Jan. 12, 2021 (GLOBE NEWSWIRE) — Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), today announced it has been named a winner in the prestigious 2021 BIG Innovation Awards presented by the Business Intelligence Group. The annual awards program recognizes the organizations, products and people that bring new ideas to life.

“We are proud to be recognized by the broader business community for this award because innovation is truly at the heart of what makes Quotient unique. Our first powerful commercial product is poised to revolutionize the donor transfusion diagnostics industry. Despite the temporary limitations triggered by the global pandemic, we know that Quotient is at a new threshold of technology disruption,” said Franz Walt, Chief Executive Officer of Quotient.

Learn more about Quotient’s game-changing system below:

MosaiQ™ by Quotient
With over 30 years’ experience in transfusion diagnostics, Quotient established itself as an innovator with its proprietary technology, MosaiQ by Quotient – the future of diagnostics. The high-throughput MosaiQ system is a fully automated and consolidated testing platform, targeting transfusion diagnostics, performing blood grouping and transfusion-transmitted infectious disease screening of donated blood. MosaiQ was specifically designed to address the challenges of today’s resource-constrained transfusion diagnostics environments.

“More than ever, the global society relies on innovation to help progress humanity and make our lives more productive, healthy and comfortable,” said Maria Jimenez, Chief Operating Officer of the Business Intelligence Group. “We are thrilled to be honoring Quotient Limited, as they are one of the organizations leading this charge and helping humanity progress.”

Organizations from across the globe submitted their recent innovations for consideration in the BIG Innovation Awards. Nominations were then judged by a select group of business leaders and executives who volunteer their time and expertise to score submissions.

For more information about Quotient’s revolutionary technology, MosaiQ by Quotient, visit: www.quotientbd.com

About Quotient Limited

Building on over 30 years of experience in transfusion diagnostics, Quotient is a commercial-stage diagnostics company committed to delivering solutions that reshape the way diagnostics is practiced. MosaiQ, Quotient’s proprietary multiplex microarray technology, offers the world’s first fully automated, consolidated testing platform, allowing for multiple tests across different modalities. MosaiQ is designed to be a game-changing solution, which Quotient believes will increase efficiencies, improve clinical practice, deliver significant workflow improvements, and operational cost savings to laboratories around the world. In response to the global effort to combat COVID-19, Quotient developed the MosaiQ COVID-19 Antibody Microarray which is CE marked and has received the U.S. FDA Emergency Use Authorization. Quotient’s operations are based in Eysins, Switzerland, Edinburgh, Scotland and Newtown, Pennsylvania.

The Quotient logo and MosaiQ™ are registered trademarks or trademarks of Quotient Limited and its subsidiaries in various jurisdictions.

Contact: Peter Buhler, Chief Financial Officer, [email protected]; +41 22 545 52 26



Posted on

GLOBAL WARMING SOLUTIONS, INC. PLANS TO ESTABLISH CORPORATE-SPONSORED SPAC (SPECIAL PURPOSE ACQUISITION COMPANY) TO ACQUIRE COMPANIES IN RENEWABLE ENERGY AND ELECTRIC VEHICLES SPACE

Jacksonville, FL, Jan. 12, 2021 (GLOBE NEWSWIRE) — Global Warming Solutions Inc. (OTC MARKET: GWSO), a developer of technologies aimed at mitigating the effects of global warming announced today its plans to establish a SPAC (Special Purpose Acquisition Company) to invest in the emerging companies in Renewable Energy and Electric Vehicles technology space.

The global renewable energy market was valued at $928.0 Billion in 2017 and is expected to reach $1,512.3 Billion by 2025, registering a CAGR of 6.1% from 2018 to 2025. Renewable energy technologies use natural sources such as wind, solar, water, and others, to transform these sources into usable forms of energy such as electricity, and mechanical energy.  The Electric Vehicles Market is projected to reach 26,951,318 units by 2030 from an estimated 3,269,671 units in 2019, at a CAGR of 21.1% during the forecast period.

SPAC’s are companies formed to raise capital in an initial public offering (“IPO”) with the purpose of using the proceeds to acquire one or more unspecified businesses or assets to be identified after the IPO. My goal as CEO of a public company is to increase shareholder’s value.  A Special Purpose Acquisition Company incorporated – sponsored by GWSO is the first step in reaching this goal”, said Vladimir Vasilenko, CEO of Global Warming Solutions, Inc.

Forward-Looking Statements

This press release may include predictions, estimates or other information that might be considered forward-looking within the meaning of applicable securities laws. While these forward-looking statements represent the Company’s current judgments, they are subject to risks and uncertainties that could cause actual results to differ materially. You are cautioned not to place undue reliance on these forward-looking statements, which reflect the opinions of the Company’s management only as of the date of this release. Please keep in mind that the Company is not obligating itself to revise or publicly release the results of any revision to these forward-looking statements in light of new information or future events. When used herein, words such as: potential, expect, look forward, believe, dedicated, building, or variations of such words and similar expressions are intended to identify forward-looking statements. Factors that could cause actual results to differ materially from those contemplated in any forward-looking statements made by the Company herein are often discussed in filings the Company makes with the United States Securities and Exchange Commission (SEC) available at www.sec.gov and on the Company’s website at https://www.gwsogroup.com.

Contact:
Vladimir Vasilenko
CEO
Global Warming Solutions, Inc.
[email protected]



Posted on

Sabra Health Care REIT Appoints Katie Cusack to its Board of Directors

Sabra Health Care REIT Appoints Katie Cusack to its Board of Directors

IRVINE, Calif.–(BUSINESS WIRE)–
Sabra Health Care REIT, Inc. (“Sabra”) (Nasdaq: SBRA) today announced the appointment of Katie Cusack to its Board of Directors.

Ms. Cusack currently serves as Chief Operating Officer of Cornell Capital LLC, a $4 billion private investment firm with offices in New York and Hong Kong. From 2007 to 2020, Ms. Cusack served in various capacities at Credit Suisse, including Chief Operating Officer for the Investment Banking Division in both Asia Pacific and Europe, Middle East and Africa, and as the Head of Ultra-High Net Worth Coverage. Prior to joining Credit Suisse, Ms. Cusack served as a Managing Director at MTS Health Partners LP, where she provided strategic advisory services to corporate clients in the health care services industry. She began her banking career at Goldman Sachs in the Mergers & Acquisitions group and Principal Investing Area.

Ms. Cusack serves in a volunteer capacity as a trustee of Hudson Guild, a Chelsea-based settlement house providing social services to over 14,000 New Yorkers.

Ms. Cusack holds an MBA from the University of Chicago Graduate School of Business and a BA in East Asian Studies from Princeton University.

Commenting on Ms. Cusack’s appointment to the Board, Rick Matros, CEO and Chairman, said, “I first became acquainted with Katie when I engaged MTS as an advisor during the Sun Healthcare Group bankruptcy and subsequent restructuring. Since then I have enjoyed watching the journey her career has taken her on. She has been successful with every move she has made. Katie brings a unique skill set and perspective to Sabra and with the recent additions of Clif Porter and Ann Kono to the Board we have materially broadened the depth, strength and diversity of the Sabra Board. As we enter our second decade, and with the promotion of Michael Costa announced today, we believe we are positioned to move forward with a leadership team second to none.”

About Sabra

Sabra operates as a self-administered, self-managed real estate investment trust (a “REIT”) that, through its subsidiaries, owns and invests in real estate serving the healthcare industry throughout the United States and Canada.

Investor & Media Inquiries:

1-888-393-8248 or [email protected]

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Health Residential Building & Real Estate Commercial Building & Real Estate Construction & Property General Health REIT

MEDIA:

Posted on

Five9 Agent Assist and Inference Studio Platform Win 2021 BIG Innovation Awards

Five9 Agent Assist and Inference Studio Platform Win 2021 BIG Innovation Awards

SAN RAMON, Calif.–(BUSINESS WIRE)–
Five9, Inc. (NASDAQ: FIVN), a leading provider of the intelligent cloud contact center, today announced that Five9 Agent Assist has been named a winner in the 2021 BIG Innovation Awards presented by the Business Intelligence Group. In addition to the recognition of the Five9 Agent Assist product, the Business Intelligence Group has also awarded the Inference Studio Platform, from Inference Solutions, the Intelligent Virtual Agent (IVA) provider recently acquired by Five9.

Five9 Agent Assist is an innovative conversational AI solution that provides contact center agents with real-time transcripts, call summaries, guidance and reminders. Agent Assist is powered by Google Contact Center AI combined with the Five9 proprietary AI model generation methodology and assisted summary ML algorithms – making it an industry-first that transforms agent performance in the contact center. With this combination, calls between agents and customers are analyzed in real-time using speech recognition and natural language processing. Based on this analysis, real-time guidance and reminders are provided to the agents allowing them to better serve their customers. Real-time call transcription and call summaries allow agents to spend less time capturing information and more time providing quick and efficient customer service.

“Five9 Agent Assist is a practical AI solution designed to provide tangible, measurable ROI in the contact center,” said Jonathan Rosenberg, CTO and Head of AI at Five9. “Businesses have recognized the necessity of providing truly great customer service experiences. With Five9 Agent Assist, agents are able to focus on the customer instead of taking notes and creating call summaries – allowing them to quickly resolve the problem with the appropriate level of human empathy. We are honored that Business Intelligence Group has recognized our advancements in AI within the CCaaS space.”

In addition, Inference Studio also received an award for making it easy for businesses of any size to automate their customer care workloads with conversational self-service, empowering human service agents to focus on the more complex and highest-value activities. The code-free SaaS platform allows non-technical business users to build and manage omnichannel IVAs that leverage leading conversational AI technologies by Google, Amazon, IBM Watson, and more. Users can customize pre-built IVA templates from Studio’s Task Library or build applications from scratch with drag and drop tools. The platform gives organizations greater choice, flexibility, and control in launching applications that deliver highly engaging and efficient customer experiences.

“The Studio platform is democratizing conversational AI by removing the biggest barriers to deploying natural language technology: cost, complexity, and the dependence on highly skilled developers,” said Callan Schebella, Five9 VP and General Manager and founder and CEO of Inference Solutions. “We thank Business Intelligence Group for recognizing this innovation as we continue shaping the future of customer service.”

“More than ever, the global society relies on innovation to help progress humanity and make our lives more productive, healthy and comfortable,” said Maria Jimenez, chief operating officer of the Business Intelligence Group. “We are thrilled to be honoring Five9 for these awards as they are one of the organizations leading this charge and helping humanity progress.”

Organizations from across the globe submitted their recent innovations for consideration in the BIG Innovation Awards. Nominations were then judged by a select group of business leaders and executives who volunteer their time and expertise to score submissions.

About Five9

Five9 is an industry-leading provider of cloud contact center solutions, bringing the power of cloud innovation to more than 2,000 customers worldwide and facilitating more than six billion call minutes annually. The Five9 Intelligent Cloud Contact Center provides digital engagement, analytics, workflow automation, workforce optimization, and practical AI to create more human customer experiences, to engage and empower agents, and deliver tangible business results. Designed to be reliable, secure, compliant, and scalable, the Five9 platform helps contact centers increase productivity, be agile, boost revenue, and create customer trust and loyalty.

For more information, visit www.five9.com.

Engage with us: @Five9,LinkedIn, Facebook, Blog, That’s Genius Podcast.

About Business Intelligence Group

The Business Intelligence Group was founded with the mission of recognizing true talent and superior performance in the business world. Unlike other industry award programs, these programs are judged by business executives having experience and knowledge. The organization’s proprietary and unique scoring system selectively measures performance across multiple business domains and then rewards those companies whose achievements stand above those of their peers.

Media Contacts:

Five9

Kendall Taylor

925-231-2196

[email protected]


Maria Jimenez

Chief Operating Officer

Business Intelligence Group

[email protected]

+1 (909) 529-2737

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Software Technology Other Technology Data Management

MEDIA:

Logo
Logo
Posted on

Dominion Radiology Associates Selects Spok Go® to Improve Radiologist and Physician Collaboration

Dominion Radiology Associates Selects Spok Go® to Improve Radiologist and Physician Collaboration

Top-rated radiology provider to expedite clinical test results by using secure communication solution, Spok Go

SPRINGFIELD, Va.–(BUSINESS WIRE)–Spok, Inc., a wholly owned subsidiary of Spok Holdings, Inc. (NASDAQ: SPOK) and a global leader in healthcare communications, announced that Dominion Radiology Associates, PLLC (DRA) has selected the Spok Go® cloud-native communication platform to activate care team collaboration between radiologists and referring physicians.

DRA is a professional physician owned practice that provides subspeciality diagnostic imaging, interventional radiology and other radiology-based supervision and interpretation services in the Greater Richmond Region and Hampton Roads/Chesapeake region of Virginia.

“It is essential for us to securely communicate and collaborate with our referring physicians throughout our service regions,” said Dr. Neil Green, chief medical informatics officer at Dominion Radiology Associates. “Spok Go allows us to quickly and efficiently communicate by secure messaging of text, photos or video to a smartphone or web portal in order to expedite imaging test results. This collaboration with ordering providers allows us to further our mission of providing the best care to our patients.”

“Not only does Spok have the secure collaboration solution we need, but the team was extremely responsive and easy to work with,” said Christopher Snyder, chief operating officer at Dominion Radiology Associates. “We are looking forward to this continued partnership and utilizing the capabilities of Spok Go in the years to come.”

“We are pleased that an organization with as strong of a reputation as Dominion Radiology Associates chose Spok as a trusted partner,” said Vincent D. Kelly, president and chief executive officer of Spok Holdings, Inc. “We are confident the capabilities of Spok Go will activate and support both internal and external care team communication for this organization. We are honored that Spok will play a key role in helping achieve both enhanced provider and patient satisfaction for DRA.”

About Dominion Radiology Associates

Dominion Radiology Associates is a physician-owned practice providing high-quality, high-value medical imaging services to residents of Virginia and Northeastern North Carolina. The group has more than 45 providers, including board-certified, fellowship-trained physicians who have graduated from some of the most respected radiology programs in the U.S., with training and experience in neuroradiology, musculoskeletal/body imaging, oncology, cardiac, breast imaging and other subspecialties. Through its collaboration with Chesapeake Regional Healthcare, the practice has served patients at Chesapeake Regional Medical Center, Chesapeake Regional Imaging’s Kingsborough and Kempsville locations and the Jennings Outpatient Center. For more information, visit dominionradiology.com.

About Spok

Spok, Inc., a wholly owned subsidiary of Spok Holdings, Inc. (NASDAQ: SPOK), headquartered in Springfield, Virginia, is proud to be a global leader in healthcare communications. We deliver clinical information to care teams when and where it matters most to improve patient outcomes. Top hospitals rely on the Spok Go® and Spok Care Connect® platforms to enhance workflows for clinicians and support administrative compliance. Our customers send over 100 million messages each month through their Spok® solutions. When seconds count and patients’ lives are at stake, Spok enables smarter, faster clinical communication. For more information, visit spok.com or follow @spoktweets on Twitter. 

Spok is a trademark of Spok Holdings, Inc. Spok Go and Spok Care Connect are trademarks of Spok, Inc. 

Katlyn Nesvold

+1 (952) 230-5584

[email protected]

KEYWORDS: United States North America Virginia

INDUSTRY KEYWORDS: Software Other Health Radiology Data Management Technology Medical Devices Hospitals Nanotechnology Biotechnology Nursing Practice Management Other Technology Health

MEDIA:

Logo
Logo
Posted on

Synopsys and Socionext Expand Collaboration to Deploy HBM2E IP for 5-Nanometer Process in AI and High-Performance Computing SoCs

Collaboration Builds on Successful Adoption of Broad DesignWare IP Portfolio in Socionext’s High-Performance AI Engine and Accelerator Solution

PR Newswire

MOUNTAIN VIEW, Calif. and YOKOHAMA, Japan, Jan. 12, 2021 /PRNewswire/ — Synopsys, Inc. (Nasdaq: SNPS) and Socionext, Inc. today announced their collaboration to expand Socionext’s use of Synopsys’ broad DesignWare® IP to include Synopsys’ HBM2E IP for maximum memory throughput in AI and high-performance computing (HPC) applications. Socionext selected Synopsys’ HBM2E IP, operating at 3.6 Gbps, to meet the stringent capacity, power, and compute performance requirements of its innovative AI engine and accelerator system-on-chip (SoC). The Synopsys IP provides efficient heterogeneous integration with the shortest 2.5D interposer package routes.

“As a global leader in SoC solutions with differentiated functionalities, we face very tight delivery deadlines,” said Yutaka Hayashi, vice president of Automotive & Industrial Business Group at Socionext. “By leveraging Synopsys’ DesignWare HBM2E IP and integrated full-system multi-die design platform, Socionext can deliver world-class high-performance, high-capacity and power-efficient SoCs on the 5-nanometer FinFET process to the market. We are also collaborating with Synopsys on using their next-generation DesignWare IP solutions including HBM3.”

With an aggregated bandwidth of 460 gigabytes per second, the DesignWare HBM2E PHY IP delivers the required massive compute performance of SoCs in advanced FinFET processes. The HBM2E IP is part of Synopsys’ comprehensive memory interface IP solution that includes DDR5/4/3/2 and LPDDR5/4//4X/3/2 IP, which have been validated in hundreds of designs and shipped in millions of SoCs.

“As the leading memory interface IP provider, Synopsys provides innovative companies, like Socionext, with a highly competitive HBM2/2E IP solution that addresses the aggressive power and memory bandwidth requirements of advanced high-performance computing SoCs,” said John Koeter, senior vice president of marketing and strategy for IP at Synopsys. “Synopsys’ silicon-proven DesignWare HBM2/2E IP, with over 25 design wins and customers in volume production, enables designers to confidently integrate the IP into their SoCs with less risk and achieve a faster path to silicon success.” 

Availability and Resources
The Synopsys DesignWare HBM2/2E IP in a wide range of processes from 16-nm to 5-nm is available now. For more information, visit the DesignWare HBM2/2E IP and 3DIC Compiler: unified platform for end-to-end multi-die integration in a package web pages.

About DesignWare IP
Synopsys is a leading provider of high-quality, silicon-proven IP solutions for SoC designs. The broad DesignWare IP portfolio includes logic libraries, embedded memories, embedded test, analog IP, wired and wireless interface IP, security IP, embedded processors, and subsystems. To accelerate prototyping, software development, and integration of IP into SoCs, Synopsys’ IP Accelerated initiative offers IP prototyping kits, IP software development kits, and IP subsystems. Synopsys’ extensive investment in IP quality, comprehensive technical support, and robust IP development methodology enable designers to reduce integration risk and accelerate time-to-market. For more information on DesignWare IP, visit http://www.synopsys.com/designware.

About Socionext
Socionext is a global, innovative enterprise that designs, develops and delivers System-on-Chip solutions to customers worldwide. The company is focused on technologies that drive todayʼs leading-edge applications in consumer, automotive and industrial markets. Socionext combines world-class expertise, experience, and an extensive IP portfolio to provide exceptional solutions and ensure a better quality of experience for customers. Founded in 2015, Socionext Inc. is headquartered in Yokohama, and has offices in Japan, Asia, United States and Europe to lead its product development and sales activities. For more information, visit www.socionext.com.

About Synopsys
Synopsys, Inc. (Nasdaq: SNPS) is the Silicon to Software™ partner for innovative companies developing the electronic products and software applications we rely on every day. As an S&P 500 company, Synopsys has a long history of being a global leader in electronic design automation (EDA) and semiconductor IP and offers the industry’s broadest portfolio of application security testing tools and services. Whether you’re a system-on-chip (SoC) designer creating advanced semiconductors, or a software developer writing more secure, high-quality code, Synopsys has the solutions needed to deliver innovative products. Learn more at www.synopsys.com.

Editorial Contact:

Kelly James

Synopsys, Inc.
650-584-8972
[email protected] 

Socionext, Inc.
+81-45-568-1006
www.socionext.com/en/contact/ 

Cision View original content:http://www.prnewswire.com/news-releases/synopsys-and-socionext-expand-collaboration-to-deploy-hbm2e-ip-for-5-nanometer-process-in-ai-and-high-performance-computing-socs-301206440.html

SOURCE Synopsys, Inc.

Posted on

Evofem Biosciences Wins Business Intelligence Group’s BIG Innovation Award 2021

Evofem honored amongst best companies globally for outstanding innovation with first-in-class non-hormonal prescription contraceptive vaginal gel, Phexxi®

PR Newswire

SAN DIEGO, Jan. 12, 2021 /PRNewswire/ — Evofem Biosciences, Inc., (NASDAQ: EVFM) has been named a winner of Business Intelligence Group’s 2021 BIG Innovation Awards for outstanding innovation with first-in-class non-hormonal prescription contraceptive vaginal gel, Phexxi® (lactic acid, citric acid and potassium bitartrate). This annual business awards program recognizes organizations, products, and people that are bringing new ideas to life in innovative ways.

“As a female-led, female-focused company, we put women’s needs first and innovate for them. We know firsthand about the serious responsibility and impact of family planning,” said Saundra Pelletier, Chief Executive Officer, Evofem Biosciences. “Despite the 18 categories of contraception, nearly half of all U.S. pregnancies are still unplanned. Women need options they can and will use, including on-demand hormone-free prescription birth control.

“Innovation is our opportunity to effect real change in women’s lives. We appreciate Business Intelligence Group for recognizing our efforts,” continued Pelletier. “Poverty elimination is profoundly impacted when a woman can choose when, if and how often she has children, and the best way to assist her is with innovation in birth control options.”

Phexxi is designed to be used immediately before or up to an hour before intercourse. It was approved by the U.S. Food and Drug Administration in May 2020, and is now available in the U.S. by prescription. Phexxi works to maintain vaginal pH, which reduces sperm mobility, lowering the chance of sperm reaching the egg, and is the first non-hormonal contraceptive method created for women in decades.

Organizations from across the globe submitted their recent innovations for consideration in the BIG Innovation Awards. Nominations were judged by a select group of business leaders and executives who volunteered their time and expertise to score submissions.

About Evofem Biosciences
Evofem Biosciences, Inc., (NASDAQ: EVFM) is a commercial-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women’s sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from certain sexually transmitted infections (STIs). The Company’s first commercial product, Phexxi® (lactic acid, citric acid and potassium bitartrate), is the first and only hormone-free, prescription vaginal gel approved in the United States for the prevention of pregnancy. The Company is evaluating EVO100 in a Phase 3 clinical trial, ‘EVOGUARD,’ for the prevention of urogenital Chlamydia trachomatis and Neisseria gonorrhoeae infection in women. For more information, please visit www.evofem.com.

Phexxi® is a registered trademark of Evofem Biosciences, Inc.

About PHEXXI®
Phexxi® (lactic acid, citric acid, and potassium bitartrate) is a prescription vaginal gel used to prevent pregnancy in females who choose to use an on-demand method of birth control. Phexxi® is only effective when used immediately before (or up to one hour before) each act of vaginal sex. Phexxi® is not effective when used after vaginal sex.

IMPORTANT SAFETY INFORMATION

WHAT ARE THE POSSIBLE SIDE EFFECTS OF PHEXXI® (lactic acid, citric acid, and potassium bitartrate) vaginal gel 1.8%, 1%, 0.4%?

If you have had a history of repeated urinary tract infections or other urinary tract problems, avoid Phexxi®.

The most common side effects were vaginal burning, vaginal itching, vaginal yeast infection, urinary tract infection, vaginal area discomfort, bacterial vaginosis, and vaginal discharge. Women also reported genital discomfort, pain while urinating, and vaginal pain. Some male partners reported genital discomfort.

What else should I know about using Phexxi®?

Phexxi® does not protect against any sexually transmitted diseases, including HIV. Avoid using Phexxi® with a vaginal ring.

Contact your healthcare provider if you are experiencing severe genital irritation or discomfort or urinary tract symptoms. Avoid Phexxi® if you or your sexual partner is allergic to lactic acid, citric acid, potassium bitartrate, or any of the ingredients in Phexxi®. Stop using Phexxi® if you develop an allergic reaction.

Please see full 

Prescribing Information

 
for Phexxi®, including Patient Information.

Please report side effects by contacting Evofem Biosciences toll-free at 1-833-EVFMBIO or contact FDA at 1-800-FDA-1088 or 

www.fda.gov/medwatch

.

Forward Looking Statements 
This press release includes “forward-looking statements,” within the meaning of the safe harbor for forward-looking statements provided by Section 21E of the Securities Exchange Act of 1934, as amended; and the Private Securities Litigation Reform Act of 1995. Various factors could cause actual results to differ materially from those discussed or implied in the forward-looking statements, and you are cautioned not to place undue reliance on these forward-looking statements, which are current only as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Important factors that could cause actual results to differ materially from those discussed or implied in the forward-looking statements, or that could impair the value of Evofem Biosciences’ assets and business, are disclosed in Evofem’s SEC filings, including its Annual Report on Form 10-K for the year ended December 31, 2019 filed with the SEC on March 12, 2020, its Current Report on Form 8-K filed with the SEC on June 2, 2020, and its Quarterly Report on Form 10-Q for the quarter ended September 30, 2020 filed with the SEC on November 9, 2020. All forward-looking statements are expressly qualified in their entirety by such factors. Evofem does not undertake any duty to update any forward-looking statement except as required by law.

About Business Intelligence Group 
The Business Intelligence Group was founded with the mission of recognizing true talent and superior performance in the business world. Unlike other industry award programs, these programs are judged by business executives having experience and knowledge. The organization’s proprietary and unique scoring system selectively measures performance across multiple business domains and rewards those companies whose achievements stand above those of their peers. 

Investor Relations Contact

Amy Raskopf

Evofem Biosciences, Inc.
[email protected]
Mobile: (917) 673-5775

Media Contact

Ellen Thomas

Evofem Biosciences, Inc.
[email protected]
Mobile: (718) 490-3248

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/evofem-biosciences-wins-business-intelligence-groups-big-innovation-award-2021-301205794.html

SOURCE Evofem Biosciences, Inc.

Posted on

Synopsys and Socionext Expand Collaboration to Deploy HBM2E IP for 5-Nanometer Process in AI and High-Performance Computing SoCs

Collaboration Builds on Successful Adoption of Broad DesignWare IP Portfolio in Socionext’s High-Performance AI Engine and Accelerator Solution

PR Newswire

MOUNTAIN VIEW, Calif. and YOKOHAMA, Japan, Jan. 12, 2021 /PRNewswire/ — Synopsys, Inc. (Nasdaq: SNPS) and Socionext, Inc. today announced their collaboration to expand Socionext’s use of Synopsys’ broad DesignWare® IP to include Synopsys’ HBM2E IP for maximum memory throughput in AI and high-performance computing (HPC) applications. Socionext selected Synopsys’ HBM2E IP, operating at 3.6 Gbps, to meet the stringent capacity, power, and compute performance requirements of its innovative AI engine and accelerator system-on-chip (SoC). The Synopsys IP provides efficient heterogeneous integration with the shortest 2.5D interposer package routes.

“As a global leader in SoC solutions with differentiated functionalities, we face very tight delivery deadlines,” said Yutaka Hayashi, vice president of Automotive & Industrial Business Group at Socionext. “By leveraging Synopsys’ DesignWare HBM2E IP and integrated full-system multi-die design platform, Socionext can deliver world-class high-performance, high-capacity and power-efficient SoCs on the 5-nanometer FinFET process to the market. We are also collaborating with Synopsys on using their next-generation DesignWare IP solutions including HBM3.”

With an aggregated bandwidth of 460 gigabytes per second, the DesignWare HBM2E PHY IP delivers the required massive compute performance of SoCs in advanced FinFET processes. The HBM2E IP is part of Synopsys’ comprehensive memory interface IP solution that includes DDR5/4/3/2 and LPDDR5/4//4X/3/2 IP, which have been validated in hundreds of designs and shipped in millions of SoCs.

“As the leading memory interface IP provider, Synopsys provides innovative companies, like Socionext, with a highly competitive HBM2/2E IP solution that addresses the aggressive power and memory bandwidth requirements of advanced high-performance computing SoCs,” said John Koeter, senior vice president of marketing and strategy for IP at Synopsys. “Synopsys’ silicon-proven DesignWare HBM2/2E IP, with over 25 design wins and customers in volume production, enables designers to confidently integrate the IP into their SoCs with less risk and achieve a faster path to silicon success.” 

Availability and Resources

The Synopsys DesignWare HBM2/2E IP in a wide range of processes from 16-nm to 5-nm is available now. For more information, visit the DesignWare HBM2/2E IP and 3DIC Compiler: unified platform for end-to-end multi-die integration in a package web pages.

About DesignWare IP

Synopsys is a leading provider of high-quality, silicon-proven IP solutions for SoC designs. The broad DesignWare IP portfolio includes logic libraries, embedded memories, embedded test, analog IP, wired and wireless interface IP, security IP, embedded processors, and subsystems. To accelerate prototyping, software development, and integration of IP into SoCs, Synopsys’ IP Accelerated initiative offers IP prototyping kits, IP software development kits, and IP subsystems. Synopsys’ extensive investment in IP quality, comprehensive technical support, and robust IP development methodology enable designers to reduce integration risk and accelerate time-to-market. For more information on DesignWare IP, visit http://www.synopsys.com/designware.

About Socionext

Socionext is a global, innovative enterprise that designs, develops and delivers System-on-Chip solutions to customers worldwide. The company is focused on technologies that drive todayʼs leading-edge applications in consumer, automotive and industrial markets. Socionext combines world-class expertise, experience, and an extensive IP portfolio to provide exceptional solutions and ensure a better quality of experience for customers. Founded in 2015, Socionext Inc. is headquartered in Yokohama, and has offices in Japan, Asia, United States and Europe to lead its product development and sales activities. For more information, visit www.socionext.com.

About Synopsys

Synopsys, Inc. (Nasdaq: SNPS) is the Silicon to Software™ partner for innovative companies developing the electronic products and software applications we rely on every day. As an S&P 500 company, Synopsys has a long history of being a global leader in electronic design automation (EDA) and semiconductor IP and offers the industry’s broadest portfolio of application security testing tools and services. Whether you’re a system-on-chip (SoC) designer creating advanced semiconductors, or a software developer writing more secure, high-quality code, Synopsys has the solutions needed to deliver innovative products. Learn more at www.synopsys.com.

Editorial Contact:

Kelly James

Synopsys, Inc.
650-584-8972
[email protected] 

Socionext, Inc.
+81-45-568-1006
www.socionext.com/en/contact/ 

 

Cision View original content:http://www.prnewswire.com/news-releases/synopsys-and-socionext-expand-collaboration-to-deploy-hbm2e-ip-for-5-nanometer-process-in-ai-and-high-performance-computing-socs-301206428.html

SOURCE Synopsys, Inc.

Posted on

ThirdEye Launches Healthcare, Government and Field Services Dedicated AR/MR Software Digital Ecosystem

The AR/MR enterprise leader now provides an end-to-end solution through its X2 MR Glasses and industry-specific software utilized by the U.S. military and enterprise customers worldwide

PRINCETON, N.J., Jan. 12, 2021 (GLOBE NEWSWIRE) — ThirdEye, a leader in augmented and mixed reality enterprise solutions, today announces the launch of its updated and patented suite of healthcare, government and field services software and accessories. ThirdEye’s clients, including the U.S. military, can now have a complete AR hardware, software and accessories experience using a single vendor.

ThirdEye created its Mobile Device Management (MDM) software to provide central IT experts with effective device management. The MDM software gives IT departments control over which Wi-Fi networks the glasses can discover, the availability of apps and other required security mechanisms.

The MR glasses and software leader also developed its RemoteEye software platform to allow remotely located senior technicians to see the actual field of view of frontline technicians. This platform found nearly a 40% savings in task time in the military, field services and engineering sectors. Currently more than 100 customers worldwide are utilizing the RemoteEye platform, which comes with the ThirdEye MR Glasses. This software not only works on the ThirdEye smart glasses, but also on tablets, laptops, phones and web browsers, allowing for total cross-platform compatibility. By utilizing this software, workers no longer need to travel on-site and can connect via AR remotely, enabling greater environmental sustainability as well.

In Healthcare, ThirdEye deployed its RespondEye software to first responders, which includes a HIPPA certified telehealth platform allowing EMS professionals to virtually connect to doctors and provide the patient with a higher quality of care from the time they arrive on the scene. Currently, the software is being offered for free for first responders in the fight against COVID-19.

“At ThirdEye, we wanted to offer the full digital AR/MR & AI ecosystem so our clients can have an end-to-end solution. To have the most impact in the healthcare industry and aid in the fight against COVID-19, we obtained our HIPAA certification for the X2 MR Glasses, our RemoteEye platform and RespondEye app for first responders. This ensures that patient data is securely accessed and that medics have the tools needed to succeed,” said Nick Cherukuri, CEO and founder of ThirdEye.

ThirdEye also offers a thermal sensor package, which allows users to view the temperatures of both people and equipment, such as HVAC systems, through an additional clip-on thermal scanner. Additionally, the company offers hard hat connections, prescription inserts and frontline connectivity packages where the glasses are bundled with wireless hotspots.

In addition, ThirdEye is expanding its partner program to enable bulk pricing discounts, free software porting help, joint webinars and marketing efforts for ISV partners and resellers. For more information on ThirdEye, visit www.thirdeyegen.com.

About ThirdEye

ThirdEye is a leader in smart glasses and AR/MR software development. While many companies today use just smart glasses or only software, ThirdEye provides a full end-to-end package for its customers and employees. It has hundreds of software developers creating apps ranging from games to entertainment to enterprise applications and its products retail around the world. From everyday consumers to Fortune 500 companies, ThirdEye is bringing the power of mixed reality globally. Mixed reality has the potential to change the way the world operates, and ThirdEye’s vision is to help generate the future.

Media Contact

Lisa Rienhardt
Uproar PR for ThirdEye
[email protected]
321.236.0102 x233